Intended Use

“MagQu” Neurofilament light IMR Reagent is used to quantitatively measure neurofilament light(NfL) in human fluid specimen, such as plasma, serum or CSF.

Use “MagQu” Neurofilament light IMR Reagent only with the XacPro-S System (MagQu Co., Ltd.).

Introduction

Neurofilament light(NfL) is a specific cytoskeletal protein highly expressed in largely myelinated axons. Increased levels of NfL in CSF and blood are clinically useful biomarkers in many neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington disease (HD). ^1,2

Principle of Test

“MagQu” Neurofilament light IMR Reagent is designed for rapid quantifying NfL by ImmunoMagnetic Reduction (IMR). We conjugate antibody on the surface of around 50 nm-in-diameter Fe₃O₄ magnetic particles. When the antibodies on the surface bind with NfL, the magnetic particles form clusters. Therefore, the ac susceptibility (Xac) of magnetic particles would be reduced in the adding ac magnetic field. By measuring the reduction of Xac, NfL can be easily, rapidly and accurately quantified.³

References

1. Lewczuk, P., Ermann, N., Andreasson, U., Schultheis, C., Podhorna, J., Spitzer, P., Maler, J. M., Kornhuber, J., Blennow, K., Zetterberg, H. (2018). Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. Alzheimer's research & therapy, 10(1), 71. doi:10.1186/s13195-018-0404-9

2. Hansson, O., Janelidze, S., Hall, S., Magdalinou, N., Lees, A. J., Andreasson, U., Norgren, N., Linder, J., Forsgren, L., Constantinescu, R., Zetterberg, H., Blennow, K., Swedish BioFINDER study (2017). Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology, 88(10), 930-937.

3. C.C. Yang, S.Y. Yang, C. S. Ho, et al., "Development of antibody functionalized magnetic nanoparticles for the immunoassay of carcinoembryonic antigen: a feasibility study for clinical use" J Nanobiotechnology. 12: 44. 2014.